ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines

Li,Wei; Jie,ZhiGang; Li,ZhengRong; Liu,Yi; Gan,Quan; Mao,YiQiu; Wang,XueMin

doi:10.3892/mmr.2014.2112

ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines

Authors:
- Wei Li
- ZhiGang Jie
- ZhengRong Li
- Yi Liu
- Quan Gan
- YiQiu Mao
- XueMin Wang
View Affiliations

Affiliations: Department of General Surgery, Jiangxi Provincial Corps Hospital, Chinese People's Armed Police Force, Nanchang, Jiangxi 330003, P.R. China, Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: April 3, 2014 https://doi.org/10.3892/mmr.2014.2112
Pages: 2423-2428

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study examined the effects of cisplatin (DDP) on gastric carcinoma cells by inhibiting the expression of excision repair cross‑complementing 1 (ERCC1) using RNA interference (RNAi). mRNA and protein expression of ERCC1 were measured in various gastric carcinoma cell lines using reverse transcription polymerase chain reaction (RT‑PCR) and western blot analysis. Cells were treated with different concentrations of DDP and the cell viability was measured using an MTT assay. The correlation between the expression of the ERCC1 gene and the resistance to DDP in the cells was determined. The specific ERCC1 small interfering RNA (siRNA) was synthesized and then transfected into SGC‑7901/DDP cells. Alterations in intracellular ERCC1 mRNA expression and protein levels were detected using RT‑PCR and western blot analysis, the number of apoptotic cells were measured using flow‑cytometry and the cell viability was measured using an MTT assay. The gene expression of ERCC1 correlated with the resistance to DDP of the cells. mRNA expression of ERCC1 was significantly reduced 24 h following transfection of ERCC1 siRNA compared with the mock control group. In addition, the number of apoptotic cells was increased and cell viability was significantly decreased in the ERCC1 siRNA‑transfected group compared with the mock control group, suggesting that the sensitivity of SGC‑7901/DDP cells to DDP had significantly increased. Cells transfected with siRNA1, siRNA2 and siRNA3 were significantly more sensitive to DPP (161, 381 and 249%, respectively) compared with the mock controls (P<0.05). The results of the present study showed that drug resistance to DDP in gastric carcinoma is correlated with increased expression of ERCC1; therefore, inhibition of ERCC1 by siRNA may ameliorate resistance to DDP in gastric carcinoma.

View Figures

View References

1	Wei J, Zou Z, Qian X, et al: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008. View Article : Google Scholar : PubMed/NCBI
2	Wang TS, Ding QQ, Guo RH, Shen H, Sun J, Lu KH, You SH, Ge HM, Shu YQ and Liu P: Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene. Biomed Pharmacother. 64:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hejna M, Wöhrer S, Schmidinger M and Raderer M: Postoperative chemotherapy for gastric cancer. Oncologist. 11:136–145. 2006. View Article : Google Scholar : PubMed/NCBI
4	Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
5	Huang ZH, Hua D and Du X: Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 64:1001–1007. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ruzzo A, Graziano F, Kawakami K, et al: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol. 24:1883–1891. 2006. View Article : Google Scholar : PubMed/NCBI
7	Wöhrer SS, Raderer M and Hejna M: Palliative chemotherapy for advanced gastric cancer. Ann Oncol. 15:1585–1595. 2004.
8	Chijiwa S, Masutani C, Hanaoka F, Iwai S and Kuraoka I: Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells. Carcinogenesis. 31:388–393. 2010. View Article : Google Scholar
9	Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 8:193–204. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kweekel DM, Gelderblom H and Guchelaar HJ: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 31:90–105. 2005. View Article : Google Scholar : PubMed/NCBI
11	Rechkunova NI and Lavrik OI: Nucleotide excision repair in higher eukaryotes: mechanism of primary damage recognition in global genome repair. Subcell Biochem. 50:251–277. 2010. View Article : Google Scholar
12	Goode EL, Ulrich CM and Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 11:1513–1530. 2002.PubMed/NCBI
13	Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer. 1:22–33. 2001. View Article : Google Scholar : PubMed/NCBI
14	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zhao H, Wang LE, Li D, Chamberlain RM, Sturgis EM and Wei Q: Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis. Carcinogenesis. 29:1560–1566. 2008.PubMed/NCBI
16	Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T and Liu B: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 8:972008. View Article : Google Scholar : PubMed/NCBI
17	Halder J, Kamat AA, Landen CN Jr, et al: Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 12:4916–4924. 2006. View Article : Google Scholar : PubMed/NCBI
18	Hannon GJ and Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature. 431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
19	Snygg AS and Elmroth SK: Expanding the chemical nature of siRNAs: oxaliplatin as metalation reagent. Biochem Biophys Res Commun. 379:186–190. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist. 10(Suppl 3): 49–58. 2005. View Article : Google Scholar : PubMed/NCBI
21	Park DJ and Lenz HJ: Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol. 6:337–344. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA, Yoon SN, Chang HJ, Yoo BC and Park JG: Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. Cancer Lett. 247:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
23	Miyashita H, Nitta Y, Mori S, et al: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncol. 39:157–162. 2003. View Article : Google Scholar : PubMed/NCBI
24	Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N and Takebayashi Y: Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer. 101:488–495. 2002. View Article : Google Scholar
25	Johnson NP, Hoeschele JD and Rahn RO: Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem Biol Interact. 30:151–169. 1980. View Article : Google Scholar : PubMed/NCBI
26	Marcuello E, Altés A, del Rio E, César A, Menoyo A and Baiget M: Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer. 112:733–737. 2004.
27	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
28	Park CH, Bessho T, Matsunaga T and Sancar A: Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem. 270:22657–22660. 1995. View Article : Google Scholar : PubMed/NCBI
29	Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX and Zhou XK: ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol. 14:6401–6407. 2008. View Article : Google Scholar : PubMed/NCBI
30	Tavernarakis N, Wang SL, Dorovkov M, Ryazanov A and Driscoll M: Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. Nat Genet. 24:180–183. 2000. View Article : Google Scholar : PubMed/NCBI
31	Hannon GJ: RNA interference. Nature. 418:244–251. 2002. View Article : Google Scholar : PubMed/NCBI
32	Chang H: RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Cancer Gene Ther. 14:677–685. 2007. View Article : Google Scholar : PubMed/NCBI
33	Shao Y, Chan CY, Maliyekkel A, Lawrence CE, Roninson IB and Ding Y: Effect of target secondary structure on RNAi efficiency. RNA. 13:1631–1640. 2007. View Article : Google Scholar : PubMed/NCBI
34	Liu G, Wong-Staal F and Li QX: Development of new RNAi therapeutics. Histol Histopathol. 22:211–217. 2007.PubMed/NCBI